Scott D Berkowitz Selected Research

Heparin (Liquaemin)

1/2020	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
9/2013	Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.
11/2003	The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
10/2002	The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.
7/2002	Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Scott D Berkowitz Research Topics

Disease

68	Hemorrhage 11/2022 - 10/2002
64	Stroke (Strokes) 01/2022 - 09/2011
43	Embolism (Embolus) 01/2022 - 09/2011
41	Atrial Fibrillation 10/2021 - 09/2011
24	Myocardial Infarction 01/2022 - 02/2013
23	Peripheral Arterial Disease 11/2022 - 01/2018
22	Ischemic Stroke 01/2022 - 09/2011
21	Venous Thromboembolism 01/2022 - 10/2002
16	Embolic Stroke 01/2022 - 09/2016
10	Venous Thrombosis (Deep-Vein Thrombosis) 12/2020 - 02/2005
9	Thrombosis (Thrombus) 10/2021 - 07/2013
8	Heart Failure 01/2021 - 07/2013
7	Coronary Artery Disease (Coronary Atherosclerosis) 10/2021 - 01/2016
7	Intracranial Hemorrhages (Intracranial Hemorrhage) 10/2021 - 09/2011
7	Pulmonary Embolism 10/2014 - 02/2005
6	Ischemia 12/2021 - 01/2018
6	Acute Coronary Syndrome 01/2019 - 07/2002
4	Vascular Diseases (Vascular Disease) 01/2021 - 01/2018
4	Body Weight (Weight, Body) 01/2021 - 10/2002
4	Infarction (Infarctions) 10/2020 - 07/2002
4	Atherosclerosis 08/2020 - 01/2019
4	Neoplasms (Cancer) 01/2020 - 09/2013
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 07/2002
3	Brain Infarction 01/2022 - 09/2016
3	Diabetes Mellitus 01/2020 - 11/2019
3	Transient Ischemic Attack 08/2019 - 03/2014
3	Carotid Artery Diseases 01/2019 - 01/2018
3	Inflammation (Inflammations) 02/2014 - 09/2013
2	Hemorrhagic Stroke 01/2021 - 07/2013
2	Cerebral Hemorrhage 01/2021 - 10/2015
2	Overweight 01/2021 - 01/2017
2	Patent Foramen Ovale 01/2020 - 12/2018
2	Chronic Obstructive Pulmonary Disease (COPD) 03/2016 - 03/2014
2	Mitral Valve Stenosis (Mitral Stenosis) 01/2016 - 12/2014
2	Anemia 12/2015 - 03/2014
2	Wounds and Injuries (Trauma) 02/2014 - 10/2005
2	Infections 02/2014 - 10/2013
1	Obesity 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Cognitive Dysfunction 10/2020
1	Intracranial Arteriosclerosis (Cerebral Atherosclerosis) 08/2020
1	Left Ventricular Dysfunction 01/2020
1	Atherosclerotic Plaque (Atheroma) 01/2020
1	Atrial Premature Complexes (Premature Atrial Contraction) 01/2019
1	Carotid Stenosis (Carotid Artery Stenosis) 01/2019
1	Intracranial Embolism 06/2018
1	Pathologic Constriction (Stenosis) 06/2018
1	Coronary Disease (Coronary Heart Disease) 01/2018
1	Unstable Angina 01/2018

Drug/Important Bio-Agent (IBA)

103	RivaroxabanIBA 11/2022 - 05/2009
42	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 10/2002
38	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2022 - 03/2014
34	Factor Xa (Coagulation Factor Xa)IBA 01/2022 - 02/2013
31	Vitamin K FDA Link 10/2021 - 01/2012
20	AnticoagulantsIBA 01/2022 - 11/2003
11	Pharmaceutical PreparationsIBA 11/2021 - 12/2010
11	Factor Xa InhibitorsIBA 12/2018 - 12/2010
7	Enoxaparin (Lovenox)FDA LinkGeneric 01/2020 - 02/2005
5	CreatinineIBA 07/2020 - 03/2011
5	Heparin (Liquaemin)FDA LinkGeneric 01/2020 - 07/2002
4	omega-Chloroacetophenone (Mace)IBA 08/2021 - 01/2020
4	ximelagatran (Exanta)IBA 10/2005 - 10/2002
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 07/2016
3	AntithrombinsIBA 10/2005 - 10/2003
2	Fibrinolytic Agents (Antithrombotic Agents)IBA 11/2017 - 09/2013
2	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 10/2014 - 02/2005
2	Thrombin FDA Link 07/2013 - 02/2005
1	Paclitaxel (Taxol)FDA LinkGeneric 11/2021
1	dicarboxydine (DCD)IBA 11/2021
1	Insulin (Novolin)FDA Link 06/2021
1	Clopidogrel (Plavix)FDA Link 12/2020
1	Hemoglobins (Hemoglobin)IBA 07/2020
1	Dihydrotachysterol (AT 10)IBA 01/2020
1	trans-crotonin (CTN)IBA 01/2020
1	apixabanIBA 01/2020
1	CholesterolIBA 01/2020
1	osocimabIBA 01/2020
1	SuspensionsIBA 01/2020
1	TabletsIBA 01/2020
1	Troponin T (Troponin T1)IBA 01/2020
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2019
1	Hemostatics (Antihemorrhagics)IBA 01/2019
1	Blood Coagulation Factors (Coagulation Factor)IBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2018
1	Tissue Plasminogen Activator (Alteplase)FDA Link 11/2017

Therapy/Procedure

29	Therapeutics 01/2022 - 07/2002
11	Surgical Amputation (Amputations) 01/2022 - 01/2018
8	Knee Replacement Arthroplasty (Total Knee Replacement) 01/2020 - 10/2002
4	Secondary Prevention 01/2020 - 07/2016
3	Polypharmacy 11/2022 - 01/2016
3	Catheters 10/2020 - 01/2018
3	Percutaneous Coronary Intervention 01/2018 - 11/2003
2	Central Venous Catheters 10/2020 - 01/2018
2	Prostheses and Implants (Prosthesis) 01/2016 - 12/2014
2	Orthopedic Procedures 02/2014 - 01/2014
2	Blood Transfusion (Blood Transfusions) 02/2014 - 10/2013
1	Drug Therapy (Chemotherapy) 06/2021
1	Endarterectomy (Thromboendarterectomy) 01/2018
1	Thrombolytic Therapy 11/2017